Galderma Laboratories has received FDA approval forVectical ointment (calcitriol 3mcg/g), a vitamin D3 product, for thetreatment of mild-to-moderate plaque psoriasis in adults. This approval wasbased on two 8-week studies that compared Vectical ointment versus a vehicletreatment. In the first study, improvements in mild-to-moderate plaquepsoriasis severity began at week 2 and were sustained over the 8-week treatmentperiod. By the end of the study, 34% of Vectical treated patients achievedtreatment success versus 22% of those treated withvehicle.
Vectical ointment will be available by prescription inpharmacies in the first quarter of 2009.
For more information call (817) 961-5000 or visit www.vectical.com.